Wells Fargo & Company Arcus Biosciences, Inc. Transaction History

Wells Fargo & Company

  • $434 Billion
  • Q3 2024

A detailed history of Wells Fargo & Company transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 18,753 shares of RCUS stock, worth $296,109. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,753
Previous 18,614 0.75%
Holding current value
$296,109
Previous $283,000 1.06%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$13.69 - $18.01 $1,902 - $2,503
139 Added 0.75%
18,753 $286,000
Q2 2024

Aug 13, 2024
SELL
$14.59 - $18.48 $11,015 - $13,952
-755 Reduced 3.9%
18,614 $283,000
Q1 2024

May 10, 2024
BUY
$14.83 - $20.18 $43,466 - $59,147
2,931 Added 17.83%
19,369 $365,000
Q4 2023

Feb 09, 2024
SELL
$13.43 - $19.63 $671,795 - $981,931
-50,022 Reduced 75.27%
16,438 $313,000
Q3 2023

Nov 13, 2023
SELL
$17.62 - $23.54 $163,636 - $218,615
-9,287 Reduced 12.26%
66,460 $1.19 Million
Q2 2023

Aug 15, 2023
SELL
$16.97 - $22.03 $96,253 - $124,954
-5,672 Reduced 6.97%
75,747 $1.54 Million
Q1 2023

May 12, 2023
BUY
$15.96 - $23.15 $1.25 Million - $1.81 Million
78,312 Added 2520.5%
81,419 $1.49 Million
Q4 2022

Feb 13, 2023
SELL
$19.7 - $35.71 $55,061 - $99,809
-2,795 Reduced 47.36%
3,107 $64,000
Q3 2022

Nov 14, 2022
BUY
$23.23 - $30.07 $3,577 - $4,630
154 Added 2.68%
5,902 $155,000
Q2 2022

Aug 12, 2022
SELL
$17.23 - $37.73 $409,074 - $895,785
-23,742 Reduced 80.51%
5,748 $145,000
Q1 2022

May 16, 2022
SELL
$28.92 - $41.83 $395,828 - $572,527
-13,687 Reduced 31.7%
29,490 $930,000
Q4 2021

Feb 14, 2022
BUY
$31.38 - $48.47 $164,086 - $253,449
5,229 Added 13.78%
43,177 $1.75 Million
Q3 2021

Nov 15, 2021
BUY
$26.93 - $37.68 $175,448 - $245,485
6,515 Added 20.73%
37,948 $1.32 Million
Q2 2021

Aug 16, 2021
SELL
$22.75 - $35.77 $445,854 - $701,020
-19,598 Reduced 38.4%
31,433 $863,000
Q1 2021

May 13, 2021
SELL
$26.16 - $41.39 $1.5 Million - $2.37 Million
-57,254 Reduced 52.87%
51,031 $1.43 Million
Q4 2020

Feb 09, 2021
BUY
$17.0 - $32.36 $310,879 - $591,767
18,287 Added 20.32%
108,285 $2.81 Million
Q3 2020

Nov 05, 2020
BUY
$17.14 - $25.47 $31,589 - $46,941
1,843 Added 2.09%
89,998 $1.54 Million
Q2 2020

Aug 13, 2020
BUY
$13.97 - $36.56 $958,425 - $2.51 Million
68,606 Added 350.94%
88,155 $2.18 Million
Q1 2020

May 14, 2020
BUY
$8.78 - $19.28 $171,640 - $376,904
19,549 New
19,549 $271,000

Others Institutions Holding RCUS

# of Institutions
201
Shares Held
51.7M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email